Optimizing development, access and implementation of clinical Dx globally

About us

IPBA has a deep understanding of the diagnostic and pharma drug development field from different stakeholders’ perspectives, and has been supporting pharmaceutical/diagnostic companies, clinical laboratories, key professional societies, governmental/regulatory agencies, on landscaping analyses, market/competitive intelligence an readiness evaluation, to define and pull off more efficient market access and implementation strategies.

Over a decade of PM projects

Worked on +200 Dx/Rx related projects for leading Pharma, Dx Co., Governments, VCs and Private Foundations.
Track record on the organizational integration and commercial implementation of precision medicine (PM) and Dx services or products into the PM business model and the various market needs and reality.

With a focus on implementation

Focus on key implementation infrastructure gaps in PM.
Global team of PM experts and local connections, built a network of over 500 laboratories.
In house deep lab dynamics knowledge, launching scenarios needs and challenges and lab analytics capability.

Underpinned by our vision

We are focused on the needs of our clients.
Healthcare provide expanding opportunities requiring real time markets feedback, change management and evolutionary business models.
We put our own skin in the game with investments in the field, driven by our solid knowledge of the markets, and appraisal of the assets from an impact-opportunity angle and potential to cover unmet needs.

IPBA has deployed an extensive field base network of partners and specialists at different levels globally, to constantly assess future actions and reactions of the variety of external stakeholders.

Our services

Implementation services

Create a suite of programs to elevate and enhance client’s team Knowledge Base – fundamental knowledge of the diagnostic ecosystem and stakeholders, at a Global level for a solid global expansion and market access strategy design.

Quantitative intel (testing metrics, installed base…).
Qualitative intel (KOLs, influencers, key centers, testing pathways…).
Competitive intel.
Country specific situation analysis.
Regulatory/ Reimbursement needs.

Elevate and enhance Client’s Diagnostic Functional Expertise and Skills – specific knowledge and skills in key areas required to ensure client’s teams have ability to create and implement plans that lead to operational excellence at time of launch in all relevant markets, and competitive risk mitigation.

Key activities occurring in specific markets to benefit from.
Opportunities and leverage points (who, where, when).
Roadmaps and actionable recommendations to expedite impact and ROI.

Establish a Strategic Dx Implementation Framework, launch planning process and internal/external training program based on the strategic and tactical elements required to be implemented for a successful LDT, IVD, CDx launch in all relevant countries.

Engagement toolkits for KOLs or stakeholders.
Messaging with strategic direction for specific accounts.
KOL engagement for AdBoards, Workshops, clinical studies definition, enrolment in clinical studies etc.
Awareness and training workshops.

Clinical and testing infrastructure

We provide a range of clinical and testing infrastructure services, including analysis calculations, supply management, cost optimization, workflow design, security implementation, logistics support, and more.

Consulting

We are focused on the precision medicine space, with a mission to improve patient access to the best diagnostics and treatments available. We specialize in connecting all stakeholders in the diagnostics and precision medicine industry to facilitate access to the market. Our services include a range of activities such as testing landscape analysis, DX-pharma partnerships, clinical-trial sponsorship, workshops, adboards, testing quality harmonization, and optimization. Our goal is to provide tailored solutions that address the unique needs of each client and improve outcomes for patients.

Team

MD, PhD, MBA President

Maria Fe Paz

Maria has 20 years experience in healthcare and the biomedical industry, that she leverages to help the healthcare industry, Rx and Dx companies, NGOs, EU/US governments, Investment Funds and Policy Regulators, with strategic biomedical consulting. Prior to founding IPBA, Maria was Chief Medical Officer at Rosetta Genomics and also CMO at Diaceutics, and Founder and President of Labceutics, where she conceptualized and built the global network of labs and contacts. She was the cornerstone to support the definition and implementation of the medical and scientific strategy for the respective teams, and for client’s projects. Maria started her entrepreneurial career in the Precision Medicine field setting up the first private molecular testing laboratories in Spain, nowadays the reference lab Hospital HM Clara Campal labs, that she sold to lead the Global Molecular Medicine Department in Pharmamar (Zeltia) Maria completed her studies at Johns Hopkins in the US, she holds an MD, a PhD as well as an MBA in NGO and Social Services Administration. She is an active member of ASCO, ESMO, AACR and ASEICA. Expert advisor to the European Commission, IMI and OECD, and Board Advisor to The International Cancer Advocacy Network, among other NGOs.

PhD Head Diagnostic Lab Liaison

Camille Garnier

From more than 10 years of experiences in major international Research Institutions, managing basic, translational and clinical studies, followed by a position as Product and Application Specialists for all Diagnostics solutions at Dako/Agilent Technologies, Camille developed a strong knowledge and expertise in a wide range of biotechnologies, Cancer Diagnostics/Therapeutics and clinical sciences. He also has extensive hands-on skills and laboratory workflow leadership. Camille holds a PhD in Biotechnologies and Oncology, performed at Institut Curie – France. During its academic period, Camille worked deeply on molecular biology, pre-clinical models, BIG DATAs, medical devices and established secured relationships with KOLs. At Agilent, he engaged in products launching, training, testing optimization, lab workflow studies. He has been also scientific and strategic advisor for Supersonic Imagine on a new market entry project.

PhD Associate Consultant – Lab Liaison

Giovanni Dothel

With over 12 years of experience in basic and translational research, Giovanni developed an academic background which empowered his broad vision of biomedical and life sciences. He started specializing in advanced basic research applied to early drug screening, later moving to the study of translational pharmacology. The fulfillment of his PhD program in Pharmacology was pursued by conceiving clinical research studies joining the biomedical centers of Bologna Academic hospital S.Orsola-Malpighi and the CURE center, University of California at Los Angeles.
His work experience, envisaging a constant interaction between basic and clinical research was later combined with a focus on the area of Medical Affairs and the cross-functionality of pharmaceutical companies.

MSc Associate Consultant – Lab Liaison

Jaume Calafell

With a strong background in biomedical sciences and translational oncology, Jaume has experience in major companies from diagnostics and personalized healthcare landscape. Prior to IPBA, he worked managing medical information at Synlab Global Diagnostics and as Medical Science Liaison of personalized healthcare at Roche, where he acquired a broad knowledge and expertise in cancer biomarkers and diagnostics, cancer therapeutics as well as in diagnostic technologies from extensive areas in the clinical laboratory. He engaged in medical and biomarker trainings, medical events and established close relationships with KOLs. Jaume also holds a MSc in Translational Biomedical Research from Vall d’Hebron Institute of Research, one of the top research institutes in Spain